Autosomal dominant polycystic kidney disease
Nephrology · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
The commonest inherited kidney disease, causing progressive cyst growth, hypertension and a march toward kidney failure, with important extrarenal features (liver cysts, intracranial aneurysms). Management controls blood pressure and, in rapid progressors, slows cyst growth with tolvaptan. First action: confirm with imaging and family history, and control blood pressure.
Red flags
- Refer to nephrology for diagnosis, progression assessment and tolvaptan consideration
- Urgent assessment for thunderclap headache (possible aneurysm rupture), cyst infection or significant haematuria
- Transplant work-up as kidney failure approaches
Assessment
Investigations
- Renal ultrasound (age-adjusted cyst criteria) or MRI; genetic testing where imaging is equivocal or for donor evaluation
- Monitor eGFR, urine ACR and BP
- Screen for intracranial aneurysm with MR angiography in those with a family history of aneurysm/SAH or high-risk occupations
Management
- Strict blood-pressure control (ACEi/ARB first-line) and generous fluid intake
- Tolvaptan (a vasopressin V2 antagonist) slows cyst growth and eGFR decline in adults at risk of rapid progression — monitor LFTs
- Treat cyst infection/haemorrhage and stones; manage pain
- Prepare for renal replacement therapy/transplantation as function declines; genetic counselling and family screening
Disposition
Refer to nephrology for diagnosis, progression assessment and tolvaptan consideration.
Complications & pitfalls
- Progressive CKD to end-stage disease, resistant hypertension, cyst infection and haemorrhage, nephrolithiasis, and subarachnoid haemorrhage from a ruptured intracranial aneurysm
Exam pearls
- A thunderclap headache in someone with ADPKD is a ruptured berry aneurysm until proven otherwise — image the head urgently, and screen for aneurysms in those with a positive family history.
- Monitoring & follow-up: Regular BP, eGFR and ACR; total kidney volume on MRI helps assess progression risk. LFTs on tolvaptan. Family screening and counselling; targeted aneurysm surveillance in at-risk individuals.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.